Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors.
about
First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System.Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa.Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues.Some recent developments regarding arthropathy and inhibitors in haemophilia.International recommendations on the diagnosis and treatment of patients with acquired hemophilia AWhen should prophylaxis therapy in inhibitor patients be considered?Clinical advances in hemophilia management.Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors.Prevention of bleeding in hemophilia patients with high-titer inhibitors.A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII.Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
P2860
Q30832356-11886139-7B29-4E38-A10A-9D661C19682DQ34436796-3C01E84E-A63D-4D62-83E5-D31F266304FEQ34999749-5A83BC3D-011E-4EE7-A01B-BD577BA4C4D7Q36981731-ED68CB19-52C9-4806-ACAF-4D969793DE1DQ37059092-5BD054AC-E0A6-470F-B863-AE92B31C8876Q37146064-F9458C94-7B24-49D0-9311-C75A1C929800Q37854874-52AAFC36-19AF-431F-A75E-1674CA07636BQ37900933-9066D819-C8C9-43F6-9313-16B0D0BD21D4Q38325328-BC20076A-B799-443E-B960-24A2FEF8D4FEQ38456352-0834EB0D-3A43-4352-AC75-B095BCAE0E5CQ39776012-80134830-E392-4A6F-9685-CC6B3F2C95AEQ41099388-F241ED5C-6448-49EF-B956-0D6FBA01D49FQ44988735-6619FEA8-43EE-453D-B7FE-AF64AED4B669Q45838031-A1003728-4CC4-45E3-9241-F2213F7A0A93Q45878007-873E761F-3B1F-4C10-ADF0-A031B867DCCDQ45882018-709CBC6A-48B9-4C0C-9876-2C98216305A1Q55346403-82B65F7E-28D6-4A16-9869-94BF4FAC739B
P2860
Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Prophylactic treatment with ac ...... haemophilia A and inhibitors.
@en
Prophylactic treatment with activated prothrombin complex concentrate
@nl
type
label
Prophylactic treatment with ac ...... haemophilia A and inhibitors.
@en
Prophylactic treatment with activated prothrombin complex concentrate
@nl
prefLabel
Prophylactic treatment with ac ...... haemophilia A and inhibitors.
@en
Prophylactic treatment with activated prothrombin complex concentrate
@nl
P2093
P2860
P1433
P1476
Prophylactic treatment with ac ...... haemophilia A and inhibitors.
@en
P2093
Leissinger CA
Valentino LA
P2860
P304
P356
10.1111/J.1365-2516.2007.01442.X
P577
2007-05-01T00:00:00Z